01/24/23 9:15 AMNasdaq : SAVA clinical trialhigh shortCassava Sciences Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer’s DiseaseADAS-Cog mean scores changed minimally over 1 year in patients with mild-to-moderate Alzheimer’s disease treated with open-label simufilam tablets. 47% of patients improved on ADAS-Cog over 1 year, and this group improved by 4.7 points. An additional 23% of patients declined less than 5 points onRHEA-AIneutral
12/20/22 9:15 AMNasdaq : SAVA managementhigh shortCassava Sciences Mourns the Death of Board Member and Officer Nadav Friedmann, PhD, MDCassava Sciences, Inc. (Nasdaq: SAVA) announced today that a valued and long-time member of the Company, Nadav Friedmann, PhD, MD, has died following a brief journey with cancer, only recently discovered. “We mourn profoundly the passing of aRHEA-AIneutral
12/06/22 9:15 AMNasdaq : SAVA high shortCassava Sciences Announces Completion of Dosing in Open-label Study of Simufilam for Alzheimer’s DiseaseOutside Biostatisticians with Specific Expertise in Alzheimer’s Disease Will Conduct an Independent Statistical Analysis on The Clinical Dataset. Clinical Dataset May Be Announced Approximately Year-End 2022, Pending Completion of Study Report by Outside Biostatisticians. AUSTIN, Texas, Dec. 06,RHEA-AIneutral
11/22/22 12:29 PMNasdaq : SAVA offeringhigh shortCassava Sciences Announces Closing of $50 Million Registered Direct OfferingCassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the closing of its previously announced registered direct offering of 1,666,667RHEA-AIneutral
11/18/22 1:30 PMNasdaq : SAVA offeringhigh shortCassava Sciences Announces $50 Million Registered Direct Offering of Common StockCassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has entered into a definitive agreement with several healthcare-focused andRHEA-AIneutral
11/07/22 9:00 AMNasdaq : SAVA earningshigh shortCassava Sciences Reports Third Quarter Financial Results for 2022 and Business UpdatesCassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stageRHEA-AInegative
11/03/22 9:15 AMNasdaq : SAVA high shortCassava Sciences Files Lawsuit Against Perpetrators of “Short and Distort” CampaignCassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced that it has filed a lawsuit in federal court against certain individuals who executed a “short and distort” campaign against the Company. The 150+ pageRHEA-AIvery negative
10/27/22 9:15 AMNasdaq : SAVA managementhigh shortCassava Sciences Announces Expansion of Leadership TeamCassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused onRHEA-AIneutral
10/13/22 9:15 AMNasdaq : SAVA high shortCassava Sciences Announces Initiation of an Open-label Extension StudyCassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stageRHEA-AIneutral
09/08/22 9:15 AMNasdaq : SAVA conferenceshigh shortCassava Sciences to Present at the H.C. Wainwright Global Investment ConferenceCassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it has been invited to present a corporate overview at the H.C. Wainwright 24 th Annual Global InvestmentRHEA-AIneutral